Other OTC - Delayed Quote • USD
HLK Biotech Holding Group, Inc. (AMHD)
At close: February 29 at 2:46 PM EST
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Anna Petinova | Interim Vice President of Administration, Interim Vice President of Finance, Treasurer and Director | -- | -- | 1964 |
| Mr. Hank Midden | Vice President - Operations | -- | -- | 1942 |
| Mr. John Gernannt | Head of Investor & Public Relations Issues | -- | -- | -- |
| Mr. Peter R. N. Maharaj | Vice President - Marketing and President - Southern Hardwoods | -- | -- | 1966 |
| Mr. Thomas Cripe | Senior Vice President of Business & Technology Development | -- | -- | -- |
| Mr. Tyler Macallister | Controller | -- | -- | -- |
HLK Biotech Holding Group, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
HLK Biotech Holding Group, Inc., through its subsidiaries, produces and sells biodiesel. It also acquires real estate properties. The company was formerly known as Amelot Holdings, Inc. and changed its name to HLK Biotech Holding Group, Inc. in February 2018. HLK Biotech Holding Group, Inc. was incorporated in 1998 and is headquartered in Norfolk, Virginia.
Corporate Governance
HLK Biotech Holding Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Feb 23, 2018Dividend Date
Upcoming Events
Upcoming Events Information Not Available